Are there any updates on the development of tigecycline patent for injection?

What companies are developing generic versions of tigecycline?

Generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) for tigecycline injection. Companies including Fresenius Kabi, Sun Pharma, and Sun Pharma Advanced Research Company have submitted applications to the FDA. Some of these ANDAs have received tentative approval, but none have launched commercially yet because the composition-of-matter patent remains active.

How long will the tigecycline patent remain active?

The primary patent covering tigecycline itself is set to expire in 2025. After that point, generic versions could enter the market once FDA approval is secured. The timing of actual launch will also depend on any additional regulatory or legal barriers, such as data exclusivity periods.

Why are companies challenging this patent?

Several generic companies have filed Paragraph IV certifications against the tigecycline patents. They assert that the patents are invalid or will not be infringed by their proposed generics. Litigation between the innovator and generic applicants is likely to determine whether generic entry occurs before or after the 2025 expiration.

When does exclusivity expire?

Data exclusivity for tigecycline injection expired several years ago. Exclusivity periods for new formulations or uses would be shorter than the patent term. Generic companies have already received tentative approvals from the FDA, which indicates they are ready to launch once patent protection lifts.

Can biosimilars enter before patent expiry?

Tigecycline is a small-molecule antibiotic, not a biologic, therefore biosimilars are not applicable. Generic small-molecule drugs can only enter after the composition-of-matter patent expires in 2025 or following settlement agreements that advance the entry date.

What side effects are patients asking about?

Patients are seeking information on the increased risk of all-cause mortality seen in Phase 3 clinical trials, mortality risk warnings in the label, and the restricted use indication for tigecycline. The FDA has issued a black-box warning for increased risk of death when used for approved indications, which has limited its clinical use in many hospitals.